{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:30:11Z","timestamp":1792931411237,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.radonc.2026.111445","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:58:25Z","timestamp":1771358305000},"page":"111445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0827","authenticated-orcid":false,"given":"Marcin","family":"Miszczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishan","family":"Sohoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-2023","authenticated-orcid":false,"given":"Shayan","family":"Smani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-8866","authenticated-orcid":false,"given":"Matthias","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Alfarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-669X","authenticated-orcid":false,"given":"Keiichiro","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2104-0058","authenticated-orcid":false,"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0259-8750","authenticated-orcid":false,"given":"Timo F.W.","family":"Soeterik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-6918","authenticated-orcid":false,"given":"Mario","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-1308","authenticated-orcid":false,"given":"Oliver","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-3673","authenticated-orcid":false,"given":"Barbara A","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111445_b0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111445_b0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0020","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.04.004","article-title":"The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0030","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111445_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.radonc.2026.111445_b0045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0050","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1259\/bjr\/31372149","article-title":"21 years of biologically effective dose","volume":"83","author":"Fowler","year":"2010","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2026.111445_b0055","unstructured":"Rohatgi A. WebPlotDigitizer v.4.6 2022. https:\/\/automeris.io\/ (accessed July 1, 2024)."},{"key":"10.1016\/j.radonc.2026.111445_b0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.radonc.2026.111445_b0065","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111445_b0070","unstructured":"RStudio Team. RStudio: Integrated Development Environment for R 2024. https:\/\/www.rstudio.com\/ (accessed April 2, 2024)."},{"key":"10.1016\/j.radonc.2026.111445_b0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijrobp.2023.11.006","article-title":"Randomized trial of concomitant hypofractionated intensity modulated radiation therapy boost versus conventionally fractionated intensity modulated radiation therapy boost for localized high-risk prostate cancer (pHART2-RCT)","volume":"119","author":"Glicksman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","article-title":"Hypofractionated dose escalation radiotherapy for high-risk prostate cancer: the survival analysis of the prostate cancer study-5 (PCS-5), a GROUQ-led phase III trial","volume":"87","author":"Niazi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111445_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijrobp.2023.05.014","article-title":"Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the prostate cancer study-5, a groupe de radio-oncologie g\u00e9nito-urinaire de quebec led phase 3 trial","volume":"118","author":"Niazi","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0090","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0095","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5603\/RPOR.a2022.0116","article-title":"Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer","volume":"27","author":"Soni","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2026.111445_b0100","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.18632\/aging.202551","article-title":"Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China","volume":"13","author":"Zhong","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.radonc.2026.111445_b0105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.19.01485","article-title":"Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer","volume":"38","author":"Avkshtol","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0110","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111445_b0115","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.7150\/jca.37825","article-title":"Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer","volume":"11","author":"Alexidis","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.radonc.2026.111445_b0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"de Vries","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0130","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.rpor.2018.06.008","article-title":"Acute toxicity and quality of life in high risk prostate cancer patients: updated results of randomized hypofractionation trial","volume":"23","author":"Karklelyte","year":"2018","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2026.111445_b0135","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO-24-02057","article-title":"Hypofractionated, dose-escalated radiation versus conventionally fractionated radiation for localized prostate cancer: long-term update of a phase III, PROSPECTIVE, randomized controlled trial","volume":"43","author":"Hassanzadeh","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0140","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111445_b0145","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0150","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.prro.2021.02.011","article-title":"Clinical outcomes of the CHIRP trial: a phase II prospective randomized trial of conventionally fractionated versus moderately hypofractionated prostate and pelvic nodal radiation therapy in patients with high-risk prostate cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00066-009-1982-z","article-title":"A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma\u00a0: a report on acute toxicity","volume":"185","author":"Norkus","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2026.111445_b0160","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"A phase III randomized controlled trial of Stereotactic Body Radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111445_b0165","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2024.05.014","article-title":"Stereotactic body proton therapy versus conventionally fractionated proton therapy for early prostate cancer: a randomized, controlled, phase 3 trial","volume":"120","author":"Toesca","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/curroncol29010003","article-title":"Prospective randomized phase II study of stereotactic body radiotherapy (SBRT) vs. conventional fractionated radiotherapy (CFRT) for Chinese patients with early-stage localized prostate cancer","volume":"29","author":"Poon","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111445_b0180","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ijrobp.2022.12.022","article-title":"Five-year patient-reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"116","author":"Lukka","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0185","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ijrobp.2022.04.006","article-title":"Acute toxicity of ultrahypofractionation compared with moderate hypofractionation in prostate cancer treatment: a randomized trial","volume":"113","author":"Kwan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijrobp.2023.11.048","article-title":"Late toxicity of prostate ultrahypofractionated radiation therapy compared with moderate hypofractionation in a randomized trial","volume":"119","author":"Alexander","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0195","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0200","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00274","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: 10-year outcomes of the FLAME trial","author":"Menne Guricov\u00e1","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111445_b0210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clon.2018.05.007","article-title":"Randomised phase II feasibility trial of image-guided external beam radiotherapy with or without high dose rate brachytherapy boost in men with intermediate-risk prostate cancer (CCTG PR15\/ NCT01982786)","volume":"30","author":"Vigneault","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2026.111445_b0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with gleason score 9\u201310 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis","volume":"71","author":"Kishan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111445_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109632","article-title":"Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients","volume":"183","author":"Miszczyk","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111445_b0230","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111445_b0235","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111445_b0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000792","article-title":"High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot","volume":"8","author":"Keam","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2026.111445_b0245","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, et al. Development and validation of an artificial intelligence digital pathology biomarker to predict benefit of long-term hormonal therapy and radiotherapy in men with high-risk prostate cancer across multiple phase III trials. J Clin Oncol 2025:JCO2400365. Doi: 10.1200\/JCO.24.00365.","DOI":"10.1200\/JCO.24.00365"},{"key":"10.1016\/j.radonc.2026.111445_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111039","article-title":"Digital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus","volume":"210","author":"Zamboglou","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0255","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0260","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111445_b0265","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111445_b0270","first-page":"00249","article-title":"Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study","volume":"S0302\u20132838","author":"Karpinski","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111445_b0275","first-page":"36","article-title":"Perirectal spacers in radiotherapy for prostate cancer - a systematic review and meta-analysis","volume":"29","author":"Miszczyk","year":"2025","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.radonc.2026.111445_b0280","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00066-024-02254-2","article-title":"Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery","volume":"200","author":"Brunner","year":"2024","journal-title":"Strahlenther Onkol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:12:53Z","timestamp":1781122373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":56,"alternative-id":["S0167814026000848"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111445","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111445"}}